Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tolerability of MDMA in Schizophrenia
NCT05770375Phase 2Recruiting
- Start
- Sep 2024
- Primary completion
- Mar 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of midomafetamine in schizophrenia. Started Sep 2024; status: recruiting.
02
Drugs
midomafetamine
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT05770375.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05770375.